Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel in ICU Patients With Severe Pneumonia.

Sponsor
Avicenna Military Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05624684
Collaborator
(none)
200
1
3.9
50.7

Study Details

Study Description

Brief Summary

The objective of this study is to assess the diagnostic performance of multiplex respiratory PCR (PCR-RM) compared to standard microbiological tests and its potential impact on the early adaptation of antibiotic treatment in intensive care patients with severe pneumonia.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Multiplex respiratory PCR

Detailed Description

This is a prospective, observational, multicenter ICU study. Adult patients with severe pneumonia requiring invasive mechanical ventilation will be included. Severe pneumonia consists of 3 categories of pneumonia: community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP), and ventilator-acquired pneumonia (VAP). The microbiological testing will be performed before antibiotic initiation on tracheobronchial aspirations, protected distal sampling, or mini-bronchoalveolar lavage as part of routine care. No additional samples will becollected for this study. Respiratory samples will be simultaneously tested by conventional microbiological techniques and multiplex respiratory PCR [PCR-RM] (BIOFIRE® FILMARRAY® Pneumonia Panel Plus). Classical microbiological culture (CMC) will be considered the gold standard for microbiological pneumonia diagnosis. The agreement between the results of the Pneumonia Plus® panel and the results of conventional microbial culture (CMC) will be assessed.

An empiric antibiotic therapy will be prescribed according to the local ecology and the protocols of each ICU unit. Two senior experts in each participating center will have to approve the antibiotic prescription. The antibiotic therapy could be modified after the reception of the Mutilpex PCR results by the two senior experts. After the reception of the results of the classic microbiological culture, the previous antibiotic changes will be judged as appropriate or inappropriate by a multidisciplinary team including intensivists, infectious disease specialists, and microbiologists. Appropriate changes include adequacy, de-escalation, and optimization of antibiotic therapy, and inappropriate changes include inadequacy, escalation, and de-optimization.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Performance and Impact of a Multiplex PCR Pneumonia Panel on the Early Adaptation of Antimicrobial Therapy in ICU Patients With Severe Pneumonia. A Prospective Multicentric Observational Study.
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Jun 1, 2023

Arms and Interventions

Arm Intervention/Treatment
ICU patients with severe pneumonia

Critically ill patients with severe pneumonia under mechanical ventilation including ventilator-associated pneumonia, community-acquired or hospital-acquired pneumonia.

Diagnostic Test: Multiplex respiratory PCR
The BIOFIRE® FILMARRAY® Pneumonia plus Panel

Outcome Measures

Primary Outcome Measures

  1. The rate of diagnostic concordance between Classical microbiological cultures and the respiratory multiplex PCR (RM-PCR) and conventional microbiological cultures (CMC) to identify pathogens responsible for severe pneumonia in critically ill patients. [through study completion, an average of 6 months]

    Classical microbiological cultures (CMC) will serve as the gold standard for the comparison between techniques, considering a test result: A true positive, when CMC and RM-PCR have identified the same microorganism (CMC+, PCR-RM +). A false positive, when RM-PCR detected an organism but not CMC (CMC-, RM-PCR+) A true negative, when no method detected any microorganism (CMC-, RM-PCR -) A false negative, when CMC but not RM-PCR has detected an organism (CMC+, RM-PCR -). Sensitivity, specificity, and positive and negative predictive values for the respiratory multiplex PCR will be calculated using the precedent findings.

  2. The impact of the respiratory multiplex PCR (RM-PCR) on the appropriateness of empirical antimicrobial therapy. [through study completion, an average of 6 months]

    The proportion of patients for whom the respiratory multiplex PCR (RM-PCR) induces an appropriate change of antibiotic therapy. Appropriate changes include adequacy, de-escalation, and escalation of antibiotic treatment. Adequacy is defined as introducing an antibiotic to cover a microorganism that was not adequately treated before the results of RM-PCR. Escalation is defined by a widening of the ATB spectrum to cover a pathogen not taken into account or the detection of resistance genes. De-escalation is defined as the use of a narrower-spectrum anti-infective or the discontinuation of an ATB combination.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • critically ill adult patients

  • clinical, biological, and radiological signs of severe pneumonia.

  • community-acquired pneumonia, hospital-acquired pneumonia, or ventilator-associated pneumonia

  • invasive mechanical ventilation.

Exclusion Criteria:
  • Non-invasive mechanical ventilation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Avicenna Military Hospital Marrakesh Marrakesh Tensift El Haouz Morocco 40000

Sponsors and Collaborators

  • Avicenna Military Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Younes Aissaoui, MD, Professor of Anesthesiology and Intensive Care Medicine - Head of surgical intensive care unit, Avicenna Military Hospital
ClinicalTrials.gov Identifier:
NCT05624684
Other Study ID Numbers:
  • MORICUP-PCR study
First Posted:
Nov 22, 2022
Last Update Posted:
Jan 31, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Younes Aissaoui, MD, Professor of Anesthesiology and Intensive Care Medicine - Head of surgical intensive care unit, Avicenna Military Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2023